Glaukos (NYSE:GKOS) Upgraded by Mizuho to Outperform Rating

Mizuho upgraded shares of Glaukos (NYSE:GKOS) from a neutral rating to an outperform rating in a research note released on Wednesday, Marketbeat reports. The firm currently has $200.00 price objective on the medical instruments supplier’s stock, up from their previous price objective of $140.00.

A number of other research firms have also recently weighed in on GKOS. Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research note on Monday, December 2nd. Truist Financial increased their price objective on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. increased their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Stifel Nicolaus increased their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. Finally, Wells Fargo & Company raised their price target on Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $159.42.

Glaukos Stock Up 5.5 %

GKOS opened at $161.30 on Wednesday. Glaukos has a 1-year low of $83.90 and a 1-year high of $163.71. The stock’s fifty day simple moving average is $152.65 and its 200 day simple moving average is $139.03. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market cap of $8.89 billion, a PE ratio of -53.41 and a beta of 1.04.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Glaukos

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new position in shares of Glaukos during the 3rd quarter valued at about $25,000. IFP Advisors Inc bought a new position in shares of Glaukos during the 4th quarter valued at about $43,000. Asset Planning Inc purchased a new stake in Glaukos during the 4th quarter valued at about $90,000. CoreCap Advisors LLC boosted its holdings in Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock valued at $112,000 after acquiring an additional 200 shares during the period. Finally, Picton Mahoney Asset Management purchased a new stake in Glaukos during the 4th quarter valued at about $125,000. 99.04% of the stock is currently owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.